Guardian Wealth Advisors LLC NC Invests $265,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Guardian Wealth Advisors LLC NC purchased a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXGet Rating) in the 1st quarter, HoldingsChannel.com reports. The firm purchased 1,015 shares of the pharmaceutical company’s stock, valued at approximately $265,000.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Norges Bank bought a new position in Vertex Pharmaceuticals during the fourth quarter valued at about $588,506,000. Wellington Management Group LLP boosted its stake in Vertex Pharmaceuticals by 23.6% during the first quarter. Wellington Management Group LLP now owns 8,053,710 shares of the pharmaceutical company’s stock valued at $2,101,776,000 after buying an additional 1,535,255 shares in the last quarter. Alliancebernstein L.P. boosted its stake in Vertex Pharmaceuticals by 15.2% during the fourth quarter. Alliancebernstein L.P. now owns 10,443,771 shares of the pharmaceutical company’s stock valued at $2,293,452,000 after buying an additional 1,374,923 shares in the last quarter. Lord Abbett & CO. LLC bought a new position in Vertex Pharmaceuticals during the first quarter valued at about $167,910,000. Finally, Aaron Wealth Advisors LLC boosted its stake in Vertex Pharmaceuticals by 25,712.2% during the first quarter. Aaron Wealth Advisors LLC now owns 591,358 shares of the pharmaceutical company’s stock valued at $2,266,000 after buying an additional 589,067 shares in the last quarter. Institutional investors own 91.33% of the company’s stock.

Insider Activity

In other Vertex Pharmaceuticals news, CEO Reshma Kewalramani sold 11,689 shares of the firm’s stock in a transaction that occurred on Friday, June 24th. The stock was sold at an average price of $291.30, for a total value of $3,405,005.70. Following the sale, the chief executive officer now owns 111,153 shares of the company’s stock, valued at approximately $32,378,868.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Vertex Pharmaceuticals news, CEO Reshma Kewalramani sold 11,689 shares of the firm’s stock in a transaction that occurred on Friday, June 24th. The stock was sold at an average price of $291.30, for a total value of $3,405,005.70. Following the sale, the chief executive officer now owns 111,153 shares of the company’s stock, valued at approximately $32,378,868.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Joy Liu sold 3,747 shares of the firm’s stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $303.90, for a total value of $1,138,713.30. Following the completion of the sale, the senior vice president now directly owns 9,605 shares in the company, valued at approximately $2,918,959.50. The disclosure for this sale can be found here. In the last quarter, insiders have sold 208,520 shares of company stock valued at $59,937,985. Insiders own 0.40% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on VRTX. HC Wainwright raised their target price on Vertex Pharmaceuticals from $275.00 to $300.00 and gave the company a “buy” rating in a research note on Friday, August 5th. Barclays upped their target price on Vertex Pharmaceuticals from $291.00 to $307.00 and gave the company an “overweight” rating in a report on Friday, August 5th. Argus upped their target price on Vertex Pharmaceuticals from $275.00 to $280.00 and gave the company a “buy” rating in a report on Monday, June 13th. Maxim Group raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $325.00 target price for the company in a report on Wednesday, June 1st. Finally, Morgan Stanley upped their target price on Vertex Pharmaceuticals from $250.00 to $253.00 and gave the company an “equal weight” rating in a report on Monday, August 8th. Six research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $291.65.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ VRTX opened at $293.48 on Tuesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.36 and a current ratio of 4.50. The firm has a market cap of $75.27 billion, a price-to-earnings ratio of 23.73, a P/E/G ratio of 2.08 and a beta of 0.45. The business’s 50-day simple moving average is $288.00 and its 200-day simple moving average is $270.64. Vertex Pharmaceuticals Incorporated has a 52 week low of $176.36 and a 52 week high of $305.95.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Rating) last issued its quarterly earnings data on Thursday, August 4th. The pharmaceutical company reported $3.60 EPS for the quarter, beating analysts’ consensus estimates of $3.12 by $0.48. The business had revenue of $2.20 billion for the quarter, compared to analyst estimates of $2.13 billion. Vertex Pharmaceuticals had a return on equity of 31.22% and a net margin of 38.26%. The firm’s revenue for the quarter was up 22.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.80 EPS. As a group, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 12.56 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Company Profile

(Get Rating)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Read More

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXGet Rating).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.